000			02040 a2200565 4500
005			20250515052603.0
264		0	_c20070202
008			200702s 0 0 eng d
022			_a1524-4563
024	7		_a10.1161/01.HYP.0000255636.11931.a2 _2doi
040			_aNLM _beng _cNLM
100	1		_aShibata, Shigeru
245	0	0	_aPodocyte as the target for aldosterone: roles of oxidative stress and Sgk1. _h[electronic resource]
260			_bHypertension (Dallas, Tex. : 1979) _cFeb 2007
300			_a355-64 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAldosterone _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aAntihypertensive Agents _xpharmacology
650	0	4	_aAntioxidants _xpharmacology
650	0	4	_aBlood Pressure _xdrug effects
650	0	4	_aCells, Cultured
650	0	4	_aCyclic N-Oxides _xpharmacology
650	0	4	_aEnzyme Activation _xdrug effects
650	0	4	_aEplerenone
650	0	4	_aHydralazine _xpharmacology
650	0	4	_aImmediate-Early Proteins _xmetabolism
650	0	4	_aInfusion Pumps
650	0	4	_aKidney _xdrug effects
650	0	4	_aMineralocorticoid Receptor Antagonists _xpharmacology
650	0	4	_aNADPH Oxidases _xmetabolism
650	0	4	_aNephrectomy _xmethods
650	0	4	_aOxidative Stress
650	0	4	_aPodocytes _xdrug effects
650	0	4	_aProtein Serine-Threonine Kinases _xmetabolism
650	0	4	_aProteinuria _xchemically induced
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aReceptors, Mineralocorticoid _xmetabolism
650	0	4	_aSpin Labels
650	0	4	_aSpironolactone _xanalogs & derivatives
650	0	4	_aTime Factors
650	0	4	_aUp-Regulation
700	1		_aNagase, Miki
700	1		_aYoshida, Shigetaka
700	1		_aKawachi, Hiroshi
700	1		_aFujita, Toshiro
773	0		_tHypertension (Dallas, Tex. : 1979) _gvol. 49 _gno. 2 _gp. 355-64
856	4	0	_uhttps://doi.org/10.1161/01.HYP.0000255636.11931.a2 _zAvailable from publisher's website
999			_c16766894 _d16766894